Notably, the study by Zhang et al., which enrolled mostly early-stage breast cancers (72.3%) and even a small portion of metastatic breast cancers (5.0%), revealed significantly longer DFS for HER2-positive breast cancers treated with trastuzumab than that for HER2-zero breast cancers [6], partially supporting our findings. The gene discussed is ERBB2; the disease is breast cancer.